Health
Verastem’s KRAS Inhibitor Shows Promise in Cancer Treatment
Verastem Oncology reports promising early results for its KRAS G12D inhibitor, a potential breakthrough treatment for advanced solid tumors like pancreatic cancer. The drug is currently being tested in over 200 patients.
Coverage timeline — 1 article
STAT News
Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…
2026-10-15 15:43 UTC